Found 107 clinical trials
Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas
Apatinib, also known as YN968D1, is a small-molecule tyrosine kinase inhibitor (TKI) that selectively binds to and inhibits vascular endothelial growth factor receptor 2 (VEGFR-2). This study aims to collect clinical, radiological and histopathology imaging including detailed radiological data, survival data, clinical parameters, molecular pathology and images of HE slices …
- 0 views
- 19 Feb, 2024
Histopathology Images Based Survival Prediction of Glioma Patients Using Artificial Intelligence
This registry aims to collect clinical, molecular and histopathology imaging including detailed survival data, clinical parameters, molecular pathology (1p/19q codeletion, MGMT methylation, IDH and TERTp mutations, etc) and images of HE slices in primary gliomas. By leveraging artificial intelligence, this registry will seek to construct and refine hstopathology imaging based …
- 0 views
- 19 Feb, 2024
Histopathology Images Based Prediction of Molecular Pathology in Glioma Using Artificial Intelligence
This registry aims to collect clinical, molecular and radiologic data including detailed clinical parameters, molecular pathology (1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations, etc) and images of HE slices in primary gliomas. By leveraging artificial intelligence, this registry will seek to construct and refine histopathology image based algorithms that …
- 0 views
- 19 Feb, 2024
MR Based Prediction of Molecular Pathology in Glioma Using Artificial Intelligence
This registry aims to collect clinical, molecular and radiologic data including detailed clinical parameters, molecular pathology (1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations, etc) and conventional/advanced/new MR sequences (T1, T1c, T2, FLAIR, ADC, DTI, PWI, etc) of patients with primary gliomas. By leveraging artificial intelligence, this registry will seek …
- 0 views
- 19 Feb, 2024
COVID-19 Staff Testing of Antibody Responses Study (Co-Stars)
This study will perform prospective repeated serological antibody testing on a cohort of at least 1000 healthcare workers at Great Ormond Street Hospital. Within this cohort, a subset of 150-250 staff members with confirmed (PCR positive) SARS-CoV-2 disease will be followed with intensive monthly testing for 6 months to determine …
- 0 views
- 19 Feb, 2024
LIPAD - LRRK2 International Parkinson's Disease Study
The study aims to identify and systematically characterize Parkinson's patients with mutations in the LRRK2 gene. In about 90% of Parkinson's patients the cause of the disease is unclear. Based on current knowledge, it can be assumed that there are several causes and that the causes may be differ between …
- 0 views
- 19 Feb, 2024
COVID-19 in Baselland: Investigation and Validation of Serological Diagnostic Assays and Epidemiological Study of Sars-CoV-2 Specific Antibody Responses
The study is to investigate the antibody response in the blood and saliva of people with a known COVID-19 infection in the canton of Baselland.
- 0 views
- 19 Feb, 2024
Association Between Lumbar Muscle Atrophy Sagittal Pelvic Alignment and Stenosis Grade in Patients With Degenerative Lumbar Spinal Stenosis
This study is to evaluate the correlation between muscle atrophy (MA), sagittal alignment, and stenosis degree in patients with lumbar spinal Stenosis (LSS). From existing radiological images, specific radiographic parameters will be extracted. General Information (Age, sex, levels of stenosis, duration of symptoms) will be extracted from patient files.
- 0 views
- 19 Feb, 2024
Molecular Diagnostic Platform for AML
This will be a translational study without any therapeutic intervention, for the purpose of analyzing the diagnostic and molecular results / characterization of adult patients with AML, regardless of the treatment they receive. Newly diagnosed or relapsed/resistant AML patients will be included.
- 0 views
- 19 Feb, 2024
Better Delineation of YY1 Related Phenotype and Epigenetic Signatures.
The investigators will gather the DNA in Montpellier genetic lab (Dr Mouna BARAT) and send the batch to the Dr Sadikovic' lab. Between 2019 and 2020, the investigators have already recruited data from individuals with YY1 pathogenic variants from several European and American genetic centres.
- 0 views
- 19 Feb, 2024